Loading clinical trials...
Loading clinical trials...
Neoadjuvant Icotinib With Chemotherapy for Resectable Stage II-IIIB N2 EGFR Mutation-positive Lung Adenocarcinoma: A Phase II Study
Conditions
Interventions
Icotinib
Cisplatin
+2 more
Locations
1
China
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
Start Date
January 1, 2022
Primary Completion Date
July 1, 2024
Completion Date
January 1, 2028
Last Updated
December 10, 2021
NCT06043817
NCT07363252
NCT06758401
NCT06476808
NCT07528066
NCT06253871
Lead Sponsor
Liaoning Cancer Hospital & Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions